Press Releases

March 31, 2008

2007: a major stage in the development of VIVALIS: 4 years of financial visibility and acceleration of R&D programmes 26 partnerships with 22 of the largest operators in the pharmaceutical industry

February 14, 2008

Quarterly report: 4th quarter 2007 High visibility on the activity: cash position of M€ 24.9 covering 4 years of operations.

February 5, 2008

VIVALIS STRENGTHENS ITS HUMAN AND TECHNICAL RESSOURCES IN THE FIELD OF THERAPEUTIC PROTEINS

January 29, 2008

VIVALIS AND KAKETSUKEN EXTEND THEIR COLLABORATION IN THE TESTING OF VIVALIS EBx® CELLS FOR THE PRODUCTION OF HUMAN AND VETERINARY VIRAL VACCINES

January 21, 2008

VIVALIS AND INNATE PHARMA SIGN A COLLABORATION AND COMMERCIAL LICENSE AGREEMENT TO DEVELOP INNATE’S NOVEL MONOCLONAL ANTIBODY, TO BE MANUFACTURED WITH VIVALIS’ EB66® PLATFORM, FOR RARE CUTANEOUS CANCERS

January 8, 2008

VIVALIS ISSUES ITS FINANCIAL CALENDAR 2008

July 2, 2007

Intercell and Novartis form world‐leading strategic partnership to drive vaccines innovation

1
…
48
49
50